Terms: = Breast cancer AND PALB2, ENSG00000083093, 79728 AND Prognosis
26 results:
1. Germline biallelic BRCA2 pathogenic variants and medulloblastoma: an international cohort study.
Kastellan S; Kalb R; Sajjad B; McReynolds LJ; Giri N; Samuel D; Milde T; Elbracht M; Holzhauer S; Niewisch MR; Kratz CP
J Hematol Oncol; 2024 Apr; 17(1):26. PubMed ID: 38685107
[TBL] [Abstract] [Full Text] [Related]
2. Treatment patterns and outcomes in metastatic castration-resistant prostate cancer patients with and without somatic or germline alterations in homologous recombination repair genes.
Olmos D; Lorente D; Alameda D; Cattrini C; Romero-Laorden N; Lozano R; Lopez-Casas PP; Jambrina A; Capone C; Vanden Broecke AM; Trevisan M; Van Sanden S; Jürgens A; Herrera-Imbroda B; Castro E
Ann Oncol; 2024 May; 35(5):458-472. PubMed ID: 38417742
[TBL] [Abstract] [Full Text] [Related]
3. Investigation of Genetic Alterations Associated With Interval breast cancer.
Rodriguez J; Grassmann F; Xiao Q; Eriksson M; Mao X; Bajalica-Lagercrantz S; Hall P; Czene K
JAMA Oncol; 2024 Mar; 10(3):372-379. PubMed ID: 38270937
[TBL] [Abstract] [Full Text] [Related]
4. High PGAP3 expression is associated with lymph node metastasis and low CD8
Hao N; Li M; Wang J; Song Y; Zhao Y; Zhang L; Yang X; Chen L; Ma J; Jia Q; Sui F
Pathol Res Pract; 2023 Nov; 251():154890. PubMed ID: 37839361
[TBL] [Abstract] [Full Text] [Related]
5. Mutations of
Tsyganov MM; Sorokovikova SS; Lutzkaya EA; Ibragimova MK
Genes (Basel); 2023 Jul; 14(8):. PubMed ID: 37628606
[TBL] [Abstract] [Full Text] [Related]
6. Multigene germline testing usefulness instead of BRCA1/2 single screening in triple negative breast cancer cases.
Arranz-Ledo M; Lastra E; Abella L; Ferreira R; Orozco M; Hernández L; Martínez N; Infante M; Durán M
Pathol Res Pract; 2023 Jul; 247():154514. PubMed ID: 37201465
[TBL] [Abstract] [Full Text] [Related]
7. Docking and Molecular Dynamics Simulation Revealed the Potential Inhibitory Activity of Amygdalin in Triple-Negative breast cancer Therapeutics Targeting the BRCT Domain of BARD1 Receptor.
Chatterjee P; Karn R; Emerson IA; Banerjee S
Mol Biotechnol; 2024 Apr; 66(4):718-736. PubMed ID: 36732462
[TBL] [Abstract] [Full Text] [Related]
8. Landscape of DNA damage response gene alterations in breast cancer: A comprehensive investigation.
Jin J; Cao J; Li B; Li T; Zhang J; Cao J; Zhao M; Wang L; Wang B; Tao Z; Hu X
Cancer; 2023 Mar; 129(6):845-859. PubMed ID: 36655350
[TBL] [Abstract] [Full Text] [Related]
9. Interdisciplinary risk counseling for hereditary breast and ovarian cancer: real-world data from a specialized center.
Zang B; Helms M; Besch L; Kalmbach N; Stegen S; Blohmer JU; Speiser D
Arch Gynecol Obstet; 2023 May; 307(5):1585-1592. PubMed ID: 36307613
[TBL] [Abstract] [Full Text] [Related]
10.
Jin TY; Park KS; Nam SE; Yoo YB; Park WS; Yun IJ
Int J Mol Sci; 2022 Mar; 23(7):. PubMed ID: 35409110
[TBL] [Abstract] [Full Text] [Related]
11. New Perspectives on the Recurrent Monoallelic Germline Mutations of DNA Repair and Checkpoint Genes and Clinical Variability.
Sahin I; Saat H
Genet Test Mol Biomarkers; 2022 Jan; 26(1):17-25. PubMed ID: 35089076
[No Abstract] [Full Text] [Related]
12. Hereditary pancreatic cancer.
Abe K; Kitago M; Kitagawa Y; Hirasawa A
Int J Clin Oncol; 2021 Oct; 26(10):1784-1792. PubMed ID: 34476650
[TBL] [Abstract] [Full Text] [Related]
13. Targeting mTOR and DNA repair pathways in residual triple negative breast cancer post neoadjuvant chemotherapy.
Anand K; Patel T; Niravath P; Rodriguez A; Darcourt J; Belcheva A; Boone T; Ensor J; Chang J
Sci Rep; 2021 Jan; 11(1):82. PubMed ID: 33420229
[TBL] [Abstract] [Full Text] [Related]
14. Clinicopathological Features and Outcomes in Individuals with breast cancer and ATM, CHEK2, or palb2 Mutations.
Bergstrom C; Pence C; Berg J; Partain N; Sadeghi N; Mauer C; Pirzadeh-Miller S; Gao A; Li H; Unni N; Syed S
Ann Surg Oncol; 2021 Jun; 28(6):3383-3393. PubMed ID: 32996020
[TBL] [Abstract] [Full Text] [Related]
15. [palb2, a major susceptibility gene for breast cancer].
Piffer A; Luporsi E; Mathelin C
Gynecol Obstet Fertil Senol; 2018 Nov; 46(10-11):701-705. PubMed ID: 30243941
[TBL] [Abstract] [Full Text] [Related]
16. Detection of novel germline mutations in six breast cancer predisposition genes by targeted next-generation sequencing.
Dong L; Wu N; Wang S; Cheng Y; Han L; Zhao J; Long X; Mu K; Li M; Wei L; Wang W; Zhang W; Cao Y; Liu J; Yu J; Hao X
Hum Mutat; 2018 Oct; 39(10):1442-1455. PubMed ID: 30039884
[TBL] [Abstract] [Full Text] [Related]
17. Mutations in BRCA1, BRCA2, and palb2, and a panel of 50 cancer-associated genes in pancreatic ductal adenocarcinoma.
Takeuchi S; Doi M; Ikari N; Yamamoto M; Furukawa T
Sci Rep; 2018 May; 8(1):8105. PubMed ID: 29802286
[TBL] [Abstract] [Full Text] [Related]
18. PARP Inhibitors in the Treatment of Triple-Negative breast cancer.
Geenen JJJ; Linn SC; Beijnen JH; Schellens JHM
Clin Pharmacokinet; 2018 Apr; 57(4):427-437. PubMed ID: 29063517
[TBL] [Abstract] [Full Text] [Related]
19. Mutation analysis of the palb2 gene in unselected pancreatic cancer patients in the Czech Republic.
Borecka M; Zemankova P; Vocka M; Soucek P; Soukupova J; Kleiblova P; Sevcik J; Kleibl Z; Janatova M
Cancer Genet; 2016 May; 209(5):199-204. PubMed ID: 27106063
[TBL] [Abstract] [Full Text] [Related]
20. Clinical outcomes in women with breast cancer and a palb2 mutation: a prospective cohort analysis.
Cybulski C; Kluźniak W; Huzarski T; Wokołorczyk D; Kashyap A; Jakubowska A; Szwiec M; Byrski T; Dębniak T; Górski B; Sopik V; Akbari MR; Sun P; Gronwald J; Narod SA; Lubiński J;
Lancet Oncol; 2015 Jun; 16(6):638-44. PubMed ID: 25959805
[TBL] [Abstract] [Full Text] [Related]
[Next]
